Loading…
InflaRx N.V. is projected to rise to $2.91 by 2027, a +14% move from its current price of $2.56. IFRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.42 | $2.56 | $2.70 | -0.14% |
| May 30 | $2.37 | $2.55 | $2.75 | -0.27% |
| May 31 | $2.32 | $2.55 | $2.80 | -0.41% |
| Jun 1 | $2.29 | $2.55 | $2.83 | -0.54% |
| Jun 2 | $2.26 | $2.54 | $2.87 | -0.68% |
| Jun 3 | $2.23 | $2.54 | $2.90 | -0.81% |
| Jun 4 | $2.20 | $2.54 | $2.92 | -0.95% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.20 | $2.54 | $2.92 | -0.95% |
| Week 2 | $2.06 | $2.51 | $3.07 | -1.88% |
| Week 3 | $1.95 | $2.49 | $3.18 | -2.81% |
| Week 4 | $1.86 | $2.46 | $3.27 | -3.73% |
| Week 5 | $1.78 | $2.44 | $3.35 | -4.64% |
| Week 6 | $1.71 | $2.42 | $3.42 | -5.54% |
| Week 7 | $1.65 | $2.40 | $3.48 | -6.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
InflaRx N.V. is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology in Germany and the United States. The C5a inflammatory mediator is used to treat a variety of autoimmune and other inflammatory diseases.
Its lead product candidate is vilobelimab, a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trials for the treatment of patients suffering from early septic organ dysfunction. Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity, has completed Phase 2a trials, and IFX002 is an advancement of vilobelimab technology in preclinical development for the treatment of chronic inflammatory indications. The company has a co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; a cell line sales agreement with Catalent Pharma Solutions LLC; and Clinical Trial Collaboration Agreements with the U.S.
DHHSs, ASPR, BARDA and PPD Development, L.P. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
InflaRx N.V. (IFRX) operates in the Healthcare sector as a clinical-stage biopharmaceutical company focused on inflammatory diseases through C5a-targeted therapies. The stock currently trades with a price of $2.61 and a market capitalization of $384.43M, reflecting its size and market positioning.
It holds a global rank of 3267. The long-run price outlook shown in the forecast indicates meaningful upside potential, with multi-year appreciation visible from 2027 onward and substantial growth culminating in a high-end forecast by 2050. The 2026 price is projected at a $2.61 average, rising to higher levels in subsequent years with increasingly attractive ROIs, signaling a bullish long-term trajectory.
A major floor 75.5% below — a decisive break under it would weaken the trend.
The nearest floor, 53.1% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 44.8% above — clearing it would confirm fresh momentum.
Key IFRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IFRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.56 | Sell | $2.57 | Sell |
| MA 10 | $2.51 | Buy | $2.51 | Buy |
| MA 20 | $2.40 | Buy | $2.32 | Buy |
| MA 50 | $1.65 | Buy | $1.86 | Buy |
| MA 100 | $1.30 | Buy | $1.54 | Buy |
| MA 200 | $1.27 | Buy | $1.38 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.10 | Neutral |
| Stoch RSI (14) | 1.83 | Buy |
| CCI (20) | 60.17 | Neutral |
| Williams %R (14) | -48.65 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -0.78 | Sell |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 51.35 | Neutral |
| TRIX (15) | 2.43 | Buy |
| Awesome (5,34) | 0.58 | Buy |
| Ultimate (7,14,28) | 56.99 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 2.67 | Sell |
| ADX (14) | 38.49 | Buy |
| ATR (14) | 0.11 | Info |
The near-term technical picture is bullish, with RSI(14) at 70 indicating strong momentum and price action currently above both the 50-day and 200-day moving averages (SMA50 = $1.58, SMA200 = $1.25). This suggests the stock is trading with positive momentum against its shorter- and longer-term trends. The 30-day range spans from $1.83 to $3.73, and a key overhead resistance sits at $2.65 while immediate support is at $1.07.
These levels provide a framework for potential swings in the coming weeks, with volatility reflected by an annualized figure of 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.825 | $2.56 | $3.67 | 0% | Neutral | |
| $2.09 | $2.91 | $4.37 | +14% | Neutral | |
| $2.59 | $3.82 | $6.11 | +49% | Bullish | |
| $3.57 | $5.54 | $9.28 | +116% | Bullish | |
| $4.26 | $6.93 | $12.08 | +171% | Bullish | |
| $4.01 | $6.82 | $12.30 | +166% | Bullish | |
| $3.97 | $7.03 | $13.07 | +175% | Bullish | |
| $4.20 | $7.76 | $14.82 | +203% | Bullish | |
| $4.29 | $8.23 | $16.12 | +222% | Bullish | |
| $6.05 | $12.08 | $24.19 | +372% | Bullish | |
| $6.21 | $13.81 | $30.37 | +439% | Bullish | |
| $19.99 | $44.41 | $102.15 | +16.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.825 | $2.56 | $3.03 | +0.00% |
| June 2026 | $1.98 | $2.37 | $2.95 | -7.40% |
| July 2026 | $1.85 | $2.26 | $2.88 | -4.57% |
| August 2026 | $1.94 | $2.40 | $3.12 | +6.26% |
| September 2026 | $1.96 | $2.45 | $3.24 | +2.04% |
| October 2026 | $1.88 | $2.37 | $3.17 | -3.43% |
| November 2026 | $1.95 | $2.48 | $3.36 | +4.81% |
| December 2026 | $2.09 | $2.68 | $3.67 | +7.97% |
Click any year to see its month-by-month IFRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IFRX is projected to trade between $0.825 and $3.67, averaging $2.56 — a potential gain of 0% from today's $2.56. Price action looks broadly range-bound.
InflaRx N.V.'s 2027 outlook centres on $2.91, within a $2.09 to $4.37 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, IFRX could reach as high as $6.11, with a base case around $3.82 and support toward $2.59 — roughly +49% from $2.56. Momentum favours further upside here.
Expect IFRX to range from $3.57 to $9.28 through 2029. The $5.54 average target implies a +116% move from current prices. That is up +45% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The IFRX price prediction for 2030 points to an average of $6.93 (low $4.26, high $12.08) — a potential gain of +171% on today's $2.56. Momentum favours further upside here.
In 2031, IFRX is projected to trade between $4.01 and $12.30, averaging $6.82 — a potential gain of +166% from today's $2.56. That is -2% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
InflaRx N.V.'s 2032 outlook centres on $7.03, within a $3.97 to $13.07 range. That is up +3% on the projected 2031 average. That marks a +175% change versus current levels. Momentum favours further upside here.
By 2033, IFRX could reach as high as $14.82, with a base case around $7.76 and support toward $4.20 — roughly +203% from $2.56. Buyers look set to stay in control over this stretch.
Expect IFRX to range from $4.29 to $16.12 through 2034. The $8.23 average target implies a +222% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The IFRX price prediction for 2035 points to an average of $12.08 (low $6.05, high $24.19) — a potential gain of +372% on today's $2.56. Buyers look set to stay in control over this stretch.
In 2040, IFRX is projected to trade between $6.21 and $30.37, averaging $13.81 — a potential gain of +439% from today's $2.56. That is up +14% on the projected 2035 average. Momentum favours further upside here.
InflaRx N.V.'s 2050 outlook centres on $44.41, within a $19.99 to $102.15 range. That is up +222% on the projected 2040 average. That marks a +16.3x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in IFRX today (≈ 390.625 IFRX) could be worth
$17,349.22
+$16,349.22 (+1635%) by 2050 · US Dollar
Based on the average projected IFRX price of $44.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IFRXwould be worth at today's price.
$1,000 invested in IFRX on May 27, 2025 (≈ 549.450534 IFRX) would be worth
$1,406.59
+$406.59 (+40.7%) today · 1.41× · US Dollar
Based on a IFRX entry price of $1.82 vs. today's $2.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.44 | $1,049.18 | +4.9% |
| 1 month ago | $1.61 | $1,590.06 | +59.0% |
| 3 months ago | $0.931 | $2,749.73 | +175.0% |
| 6 months ago | $1.26 | $2,031.75 | +103.2% |
| 1 year ago | $1.82 | $1,406.59 | +40.7% |
| All time (5.0y) ago | $2.96 | $864.86 | -13.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IFRX forecast.
Our base-case forecast reaches $5.10 around 2029.
Implied market cap at $5.10: $751.19M
The multi-year forecast shows a sustained bullish trajectory with the 2026 average price at $2.61 and rising in later years to a 2030 average of $6.93 and a 2040 average of $13.83, before reaching a 2050 average of $43.65. Projected ROIs rise from 0% in 2026 to 165.4% in 2030, then to 164.2% (2031), 168.7% (2032), 195.2% (2033), 220.8% (2034), 363.4% (2035), 430.1% (2040) and a striking 1572.4% by 2050. The forecast depicts bullish sentiment from 2027 onward, with progressively higher average prices and large potential upside, though these figures are estimates and not guarantees.
As always, investors should consider the inherent uncertainties and market risks.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $6.93, with a min of $4.26 and a max of $12.08, and a projected ROI of 165.4% in a bullish scenario.
Forecasts indicate a bullish trajectory from 2027 onward, with rising averages and strong ROI, including 2035 ROI of 363.4% and 2050 ROI of 1572.4%, though these are estimates and not guarantees.
Yes. The 2050 forecast lists a max of $100.39, indicating a potential path to that level in the long term.
Current price is $2.61 and market cap is $384.43M.
The 30-day range is $1.83 to $3.73, with RSI(14) at 70, a support level of $1.07 and resistance at $2.65, indicating a bullish near-term setup.
InflaRx N.V. Community Discussion
0Share your InflaRx N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.